Potential Benefits. 1. Opioids (morphine-like substances) are more effective in the treatment of acute pain than chronic pain. While opioids can at times abolish acute pain, the expected reduction of chronic pain is only about 20% at the beginning of the treatment period.
Potential Benefits. The benefit of sharing this information will be improved support to those affected by cuckooing; leading to reduced risk, increased safety, health and well being of adults
Potential Benefits. Potential benefits include improvement in the study participant’s lung function and other improvements that may be associated with improved lung function.
Potential Benefits. Potential benefits you may experience as a participant in the study include having improved lung function and other improvements that may be associated with improved lung function, such as improved quality of life. If it is determined that control group participants still meet study eligibility criteria and it seems clinically appropriate for them after their 1-year follow-up visit, the study sponsor will pay for these participants to undergo the EBV and bronchoscopy procedure. Potential Risks The primary risks associated with use of the Pulmonx EBV are similar to other bronchoscopic and surgical procedures used to treat emphysema. These are listed below. While this list is comprehensive, there may be other risks that are still unknown. The close monitoring that you will receive, as part of the study, should allow for detection of symptoms, should they be present. This, in turn, should allow for early intervention by your physician if that is necessary. Your physician will review all of the risks below with you so that you understand them. Previous clinical trial experience and experience from other countries around the world, where the EBV device is commercially available, has shown that in some people EBV treatment is associated with having a pneumothorax as a potential complication. A pneumothorax is a condition in which air leaks from the lung into the space between the lung and chest wall. This prevents the healthy lung from working well and can cause chest pain and shortness of breath. As many as 1 in 5 patients may experience a pneumothorax after the study procedure. Most of these tend to occur in the early period following the valve placement and usually resolve after staying in hospital for a few days. Most frequently, a treatment using a small tube to drain out the air is required. In rare cases, a pneumothorax may require a surgical intervention. In addition, there is a chance that it can be a serious and life- threatening complication. Potential Risks (Adverse Events) Acute bronchitis (inflammation or infection of the airways) Acute bronchospasm (spasm of the airway; may result in wheezing or increased shortness of breath) Acute respiratory distress syndrome (sudden, severe injury to lungs) Airway blockage due to implant migration Airway perforation (hole in the airway wall) Airway stenosis (narrowing) Anxiety Aphonia (difficulty talking) Aspiration (inhalation of vomit) Bowel function impairment Bronchial (airway) trauma or ulceration Chest pa...
Potential Benefits. This cumulative data will be used as baseline information to partially assess the effectiveness of efforts to reduce the pollutant load to the wastewater collection system and measures designed to protect the watershed. Other anticipated benefits include a potential reduction of the concentration of toxic metals in the “Dyno Dirt” class AAA composted biosolids produced at the Pecan Creek Water Reclamation Plant. The potential reduction of metals concentrations in the compost will be assessed in relation to the accumulated baseline data.All of these benefits depend upon the City’s ability to allocate resources to maximize effort and minimize economic burden. The City of Xxxxxx firmly believes that with minor enhancement of our current organizational structure, a watershed protection program can be developed that will meet the intent of the Clean Water Act at a cost acceptable to rate payers.
Potential Benefits. The subject may or may not benefit from this study. Although CBBCT device has been approved by the FDA, the use of contrast agent in CBBCT scan has not received FDA approval. If unusual/unexpected findings are noted only in CE-CBBCT, the patient will be referred for further workups. It is possible, though not probable, that the patient may have important breast problems identified because of the additional imaging she undergoes with CE-CBBCT.
Potential Benefits. There is a potential benefit to participants of this study who are seeking temporary relief of axillary hyperhidrosis symptoms. Results of the study may contribute to developing an ultrasound-based, non-invasive axillary hyperhidrosis procedure.
Potential Benefits. On the basis of the data available to date28, NI-0501 administration has shown the potential to improve or resolve relevant clinical and laboratory abnormalities of HLH, including CNS signs and symptoms when present, allowing most of the patients to proceed to HSCT (9 out of 15 patients who have completed the study with 3 additional patient ready for HSCT pending donor availability). Three patients underwent HSCT only after 4 weeks of NI-0501 treatment. The response to NI-0501 seems independent of: - the presence and type of causative mutations - the presence and type of an infectious trigger - the line of treatment, although data obtained in patients in first line are still limited. For more details refer to the latest Investigator’s Brochure (presently version 5.0, dated 20 January 2016).
Potential Benefits. Your child will get a test for anemia right now. Your child will receive treatment for malaria and if she or he has anemia, she or he will be treated for that, too. Secondly, while your child is enrolled in the study, your child can see a study clinician at Machinga District Hospital free of charge. We will provide free treatment for malaria, anemia and treatment for common illnesses that do not require hospitalization. The study will not be able to pay for any cost of hospitalization of your child unless your child is suffering from malaria.
Potential Benefits. Participation in the COVID-19 Immunity Task Force (CITF) is not likely to provide a direct benefit to the individual health or well-being of research participants. Participation in the CITF will help collect accurate data about COVID-19 immunity that will potentially help in the creation or use of tests and treatments or otherwise improve the quality of COVID-19 healthcare delivery. Participation in the CITF will also help collect accurate data about COVID-19 seroprevalence and infection rates among the general population. This can potentially help in the creation of treatments or otherwise improve the quality of COVID-19 healthcare delivery. It can also help form an accurate picture of COVID-19 incidence and immunity among the general population, which allows healthcare bodies and public health authorities to develop a more accurate pandemic response and to allocate healthcare resources more effectively.
